Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis (Q34023772)

30 July 2017

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis (English)

1 reference

postmenopausal osteoporosis

30 July 2017

0 references

1 reference

1 reference

Felicia Cosman

1

1 reference

30 July 2017

Erik Fink Eriksen

2

1 reference

30 July 2017

Chris Recknor

3

1 reference

30 July 2017

Paul D Miller

4

1 reference

30 July 2017

Núria Guañabens

5

1 reference

30 July 2017

Christian Kasperk

6

1 reference

30 July 2017

Philemon Papanastasiou

7

1 reference

30 July 2017

Aimee Readie

8

1 reference

30 July 2017

Hanumantha Rao

9

1 reference

30 July 2017

Jürg A Gasser

10

1 reference

30 July 2017

Christina Bucci-Rechtweg

11

1 reference

30 July 2017

Steven Boonen

12

1 reference

30 July 2017

1 March 2011

1 reference

Journal of Bone and Mineral Research

30 July 2017

1 reference

30 July 2017

26

1 reference

30 July 2017

3

1 reference

30 July 2017

503-511

1 reference

Treatment of osteoporosis and prevention of new fractures: role of intravenously administered bisphosphonates

30 July 2017

1 reference

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

Parathyroid hormone treatment for osteoporosis

21 January 2018

1 reference

Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure

21 January 2018

1 reference

Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis

21 January 2018

1 reference

Teriparatide or alendronate in glucocorticoid-induced osteoporosis

21 January 2018

1 reference

Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass

21 January 2018

1 reference

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy

21 January 2018

1 reference

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate

21 January 2018

1 reference

Daily and cyclic parathyroid hormone in women receiving alendronate

21 January 2018

1 reference

Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis

21 January 2018

1 reference

Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate

21 January 2018

1 reference

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

21 January 2018

1 reference

Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.

21 January 2018

1 reference

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study

21 January 2018

1 reference

Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses

21 January 2018

1 reference

Antifracture efficacy of antiresorptive agents are related to changes in bone density.

21 January 2018

1 reference

Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium

21 January 2018

1 reference

A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide

21 January 2018

1 reference

Does early PTH treatment compromise bone strength? The balance between remodeling, porosity, bone mineral, and bone size

21 January 2018

1 reference

Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity.

21 January 2018

1 reference

Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women

21 January 2018

1 reference

PTH-analogs: comparable or different?

21 January 2018

1 reference

Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy

21 January 2018

1 reference

Establishing a Reference Interval for Bone Turnover Markers in 637 Healthy, Young, Premenopausal Women From the United Kingdom, France, Belgium, and the United States

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JBMR.238

1 reference

30 July 2017

1 reference